Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response

References

• Jaffe, E, Harris, N, Stein, H, Vardiman, J. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC. 2001
   Google Scholar
• Armitage J O. How I treat patients with diffuse large B-Cell lymphoma. Blood 2007; 110: 29–36
   PubMed Web of Science ®Google Scholar
• Lossos I S, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 995–1007
   PubMed Web of Science ®Google Scholar
• Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
   PubMed Web of Science ®Google Scholar
• Barrans S L, Carter I, Owen R G, Davies F E, Patmore R D, Haynes A P, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84
   PubMed Web of Science ®Google Scholar
• Lossos I S, Alizadeh A A, Rajapaksa R, Tibshirani R, Levy R. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 2003; 101: 433–440
   PubMed Web of Science ®Google Scholar
• Kerbauy F R, Colleoni G W, Saad S T, Regis Silva M R, Correa Alves A, Aguiar K C, et al. Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature. Leuk Lymphoma 2004; 45: 2071–2078
   PubMed Web of Science ®Google Scholar
• Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183–3190
   PubMed Web of Science ®Google Scholar
• Swift L P, Rephaeli A, Nudelman A, Phillips D R, Cutts S M. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006; 66: 4863–4871
   PubMed Web of Science ®Google Scholar
• Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421–429
   PubMed Web of Science ®Google Scholar
• Bottero V, Busuttil V, Loubat A, Magne N, Fischel J L, Milano G, et al. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001; 61: 7785–7791
   PubMed Web of Science ®Google Scholar
• Kurz E U, Douglas P, Lees-Miller S P. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004; 279: 53272–53281
   PubMed Web of Science ®Google Scholar
• Reinhardt H C, Aslanian A S, Lees J A, Yaffe M B. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11: 175–189
   PubMed Web of Science ®Google Scholar
• Lam L T, Davis R E, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005; 11: 28–40
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain A R, Siraj A K, Manogaran P S, Al-Jomah N A, Moorji A, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108: 4178–4186
   PubMed Web of Science ®Google Scholar
• Mehra S, Messner H, Minden M, Chaganti R S. Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Genes Chromosomes Cancer 2002; 33: 225–234
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Xiao H, Murty V V, Chen W, Ray B, Reuter V E, et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998; 16: 2345–2349
   PubMed Web of Science ®Google Scholar
• Scudiero D A, Shoemaker R H, Paull K D, Monks A, Tierney S, Nofziger T H, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827–4833
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Heath S C, Bosl G J, Studer L, Chaganti R S. Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells. Cell Growth Differ 2002; 13: 257–264
   PubMedGoogle Scholar
• Chadalavada R S, Houldsworth J, Olshen A B, Bosl G J, Studer L, Chaganti R S. Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells. Funct Integr Genomics 2005; 5: 59–69
   PubMedGoogle Scholar
• Eisen M B, Spellman P T, Brown P O, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863–14868
   PubMed Web of Science ®Google Scholar
• Irizarry R A, Hobbs B, Collin F, Beazer-Barclay Y D, Antonellis K J, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249–264
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, Hurt E H, Wiestner A, Staudt L M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 9991–9996
   PubMed Web of Science ®Google Scholar
• Chen W, Houldsworth J, Olshen A B, Nanjangud G, Chaganti S, Venkatraman E S, et al. Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas. Blood 2006; 107: 2477–2485
   PubMed Web of Science ®Google Scholar
• Smyth G K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3(Article 3)
   PubMedGoogle Scholar
• Storey J. A direct approach to false discovery rates. J R Stat Soc 2002; 64: 479–498
   Google Scholar
• Rao P H, Houldsworth J, Dyomina K, Parsa N Z, Cigudosa J C, Louie D C, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998; 92: 234–240
   PubMed Web of Science ®Google Scholar
• Palanisamy N, Abou-Elella A A, Chaganti S R, Houldsworth J, Offit K, Louie D C, et al. Similar patterns of genomic alterations characterize primary mediastinal large-B-cell lymphoma and diffuse large-B-cell lymphoma. Genes Chromosomes Cancer 2002; 33: 114–122
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Olshen A B, Cattoretti G, Donnelly G B, Teruya-Feldstein J, Qin J, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood 2004; 103: 1862–1868
   PubMed Web of Science ®Google Scholar
• Furman R R, Asgary Z, Mascarenhas J O, Liou H C, Schattner E J. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000; 164: 2200–2206
   PubMed Web of Science ®Google Scholar
• Davis R E, Brown K D, Siebenlist U, Staudt L M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861–1874
   PubMed Web of Science ®Google Scholar
• Vasanwala F H, Kusam S, Toney L M, Dent A L. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 2002; 169: 1922–1929
   PubMed Web of Science ®Google Scholar
• Robles A I, Wright M H, Gandhi B, Feis S S, Hanigan C L, Wiestner A, et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res 2006; 12: 6547–6556
   Google Scholar
• Chang H, Blondal J A, Benchimol S, Minden M D, Messner H A. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines. Leuk Lymphoma 1995; 19: 165–171
   PubMed Web of Science ®Google Scholar
• Eom Y W, Kim M A, Park S S, Goo M J, Kwon H J, Sohn S, et al. Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 2005; 24: 4765–4777
   PubMed Web of Science ®Google Scholar
• Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297–309
   PubMed Web of Science ®Google Scholar
• Monti S, Savage K J, Kutok J L, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851–1861
   PubMed Web of Science ®Google Scholar
• He L, Thomson J M, Hemann M T, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828–833
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639–16647
   PubMed Web of Science ®Google Scholar
• Strauss S J, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D, et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007; 67: 2783–2790
   PubMed Web of Science ®Google Scholar
• Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai Y T, et al. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006; 134: 145–156
   PubMed Web of Science ®Google Scholar
• Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628–9632
   PubMed Web of Science ®Google Scholar
• Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa S, et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 1999; 397: 702–706
   PubMed Web of Science ®Google Scholar
• Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene 2001; 20: 8326–8333
   PubMed Web of Science ®Google Scholar
• Smith P G, Wang F, Wilkinson K N, Savage K J, Klein U, Neuberg D S, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005; 105: 308–316
   PubMed Web of Science ®Google Scholar
• Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007
   Web of Science ®Google Scholar
• Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D, et al. PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 2008; 111: 285–291
   PubMed Web of Science ®Google Scholar
• Andreadis C, Gimotty P A, Wahl P, Hammond R, Houldsworth J, Schuster S J, et al. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 2007; 109: 3409–3416
   PubMed Web of Science ®Google Scholar